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The widespread use of the inadequately defined term ‘‘leptin resistance’’ led the National Institutes of Health
to convene a workshop aimed at developing a quantitative definition of this term that would facilitate mech-
anistic research into leptin’s actions in human health and disease. Although leptin-responsive conditions are
recognized, the field is limited by a lack of robust, easily quantifiable behavioral or metabolic biomarkers of
the hormone’s action. Further advances require biomarkers that can be used to identify patients who may
benefit from leptin therapy and that are useful for understanding the determinants of clinical leptin respon-
siveness.Overview
The phrase ‘‘leptin resistance’’ arose not long after the discovery
of this adipose tissue-derived hormone in late 1994 (Frederich
et al., 1995a; Zhang et al., 1994). Found in more than 4,000 cita-
tions since (Figure 1), ‘‘leptin resistance’’ appears to connote
diverse meanings in distinct contexts and to different investiga-
tors, including obesity in the face of hyperleptinemia, and the
failure of pharmacologic leptin to suppress feeding (Froy et al.,
2011; Miyazaki et al., 2009; Stradecki and Jaworski, 2011).
The disparate and confusing usage of the term ‘‘leptin resis-
tance’’ led the National Institute of Diabetes and Digestive and
Kidney Diseases at the National Institutes of Health (NIH) to
hold a workshop, ‘‘Toward a Clinical Definition of Leptin Resis-
tance,’’ on February 25, 2011. The goal of the expert attendees
(see the Supplemental Information available online) at the
meeting was to explore current usage of the phrase ‘‘leptin resis-
tance’’ and to work toward a quantifiable, clinically useful defini-
tion that could be used to identify patient populations that would
benefit from leptin therapy. Some of the questions discussed at
the 1 day workshop were as follows:
d The term ‘‘leptin resistance’’ has been applied diversely to
mean different things in different contexts. Can a general
definition be found?
d What studies need to be done to establish a useful defini-
tion of leptin resistance in people?
d Do appropriate tools exist to measure leptin resistance in
human subjects?
d What clinical populations are candidates for leptin
therapy? Are there therapies that can increase leptin sensi-
tivity?
d Is obesity always accompanied by leptin resistance?150 Cell Metabolism 15, February 8, 2012 ª2012 Elsevier Inc.This perspective summarizes the general conclusions of the
meeting (Box 1).
Leptin Biology
Leptin, a 16 kDa cytokine, is produced by adipose tissue in
approximate proportion to adipose tissue mass (Considine
et al., 1996; Frederich et al., 1995a, 1995b). Thus, circulating lep-
tin concentrations generally reflect the status of long-term
adipose tissue energy stores, and are usually greater in obese
compared to lean individuals (Considine et al., 1996; Frederich
et al., 1995a, 1995b). Leptin modulates a host of physiologic
processes and behaviors in line with the need for these reserves
(Ahima et al., 1996; Myers et al., 2009). For instance, adequate
fat stores/leptin concentrations diminish the drive to feed, while
enabling energy expenditure via a variety of neuroendocrine
axes and autonomic outputs. Conversely, inadequate or falling
leptin concentrations (e.g., during caloric restriction or stable
weight reduction) increases the desire to eat, decreases energy
utilization, and promotes a variety of behavioral adaptations to
diminished energy stores. Leptin also supports reproductive
competence and immune function and contributes to the
regulation of metabolic homeostasis (by modulating insulin
secretion, hepatic glucose production, and lipid metabolism),
as well as some aspects of bone biology (Ducy et al., 2000;
Farooqi et al., 2002; Kulkarni et al., 1997; Liang and Tall, 2001;
Minokoshi et al., 2002; Nogueiras et al., 2007; Pocai et al.,
2005; Stafford et al., 2008; Wang et al., 2010). The biological
effects of leptin action suggest its potential therapeutic utility in
a variety of pathologic states, including obesity and diabetes
and their comorbid diseases. Indeed, leptin effectively treats
the metabolic complications of lipodystrophy syndromes and
restores menstruation in hypothalamic amenorrhea (Kelesidis
Figure 1. Number of Publications per Year Citing ‘‘Leptin
Resistance’’ Since the Hormone’s Discovery
Data are from PubMed.
Box 1. Main Themes Generated at the Workshop
d The term ‘‘leptin resistance’’ is commonly used as
a catchall phrase for states of obesity in which hyperlepti-
nemia and/or decreased responsiveness to leptin adminis-
tration is observed. These conditions are rarely the result of
a primary Lepr defect.
d Were leptin resistance to be defined as the coexistence of
hyperleptinemia in obesity, this would merely serve to
highlight the elevated concentration of a single hormone
whose production is expected to be increased in this
condition. Furthermore, leptin retains physiologic rele-
vance even when elevated in obesity, and alterations in
leptin action may or may not be primary to the genesis of
obesity. Thus, referring to the coexistence of hyperleptine-
mia in obesity as ‘‘leptin resistance’’ imbues the term with
little meaning.
d Despite some utility of the term as used to describe relative
insensitivity to exogenous leptin, ‘‘leptin resistance’’
implies neither a single specific mechanism nor a specific
metric of leptin action. Because of the pluripotent effects of
leptin and the numerousways in which its action is studied,
the universal application of a narrow definition of leptin
resistance appears unlikely to be practical or useful in
most contexts.
d Pragmatically, when considering leptin as a potential
clinical therapeutic agent, predictors of therapeutic
responsiveness to exogenous leptin rather than a precise
universal ‘‘leptin resistance’’ definition represent the
most important consideration.
d We currently lack good predictors of, and acute assays to
define, leptin responsiveness in humans. Such tools are
needed to identify those who might be helped by leptin
administration. The performance of studies to define
potentially sensitive groups, with rapid dissemination of
the resultant data, represents a high priority.
d Further clinical studies are also required to examine
mechanisms by which leptin sensitivity may potentially
be increased, and to determine predictors that identify
individuals who may benefit most from such sensitizing
treatments.
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ated with apparently diminished metabolic efficacy of leptin
(‘‘leptin resistance,’’ see below) has, however, complicated its
potential use to treat obesity.
Mechanisms of Action
Leptin acts via its cell surface receptor (LEPR): while there exist
multiple LEPR isoforms that result from alternative splicing of the
Lepr mRNA, the LEPR-B form of the receptor mediates essen-
tially all known physiologic effects of leptin (Chua et al., 1996,
1997; Tartaglia et al., 1995). LEPR-B is a type 1 cytokine receptor
that mediates intracellular signaling via an associated Janus
family tyrosine kinase (Jak2) (Baumann et al., 1996; Robertson
et al., 2008). Major intracellular signaling pathways emanating
from activated LEPR-B include the phosphorylation and activa-
tion of signal transducer and activator of transcription (STAT)
proteins (STAT3 and STAT5), the PTPN11/extracellular regu-
lated kinase (ERK) pathway, and the feedback inhibition pathway
mediated by the suppressor of cytokine signaling-3 (SOCS3)
(Bjorbaek et al., 1998; Robertson et al., 2008). Another inhibitory
pathway involves protein tyrosine phosphatase-1B (PTP1B;
a.k.a. PTPN1) (Zabolotny et al., 2002). Both SOCS3 and
PTP1B decrease leptin sensitivity and response in vitro and
in vivo (Bjorbaek et al., 1998, 1999; Bjorbak et al., 2000; Bjorn-
holm et al., 2007; Zabolotny et al., 2002) (Figure 2).
Most known leptin action is attributable to its effects in the
brain, where LEPR-B is predominantly expressed (Cohen et al.,
2001; de Luca et al., 2005; Elmquist et al., 1998; Myers et al.,
2009). Leptin action and LEPR-B expression have also been re-
ported in a variety of tissues outside of the brain, including some
cells of the immune system (Matarese et al., 2005). There is little
evidence to support a role for peripheral LEPR-B expression in
the control of whole-body energy balance or glucose homeo-
stasis, however. CNS leptin has been shown to mediate most
leptin actions, including control of neuroendocrine axes, the
autonomic nervous system, satiety, and the limbic system, as
well as numerous behaviors. A great deal of research in this
area has focused on important neurons of the hypothalamic
arcuate nucleus that express proopiomelanocortin or Agouti-
related peptide, but direct leptin action on these neurons
accounts for only a fraction of total leptin action, and LEPR-B
is highly expressed in several other brain regions associatedwith the control of feeding-related behaviors and energy expen-
diture—including multiple hypothalamic, midbrain, and brain-




The biology of leptin, as outlined above, was elucidated by
studying leptin deficiency and examining the effects of leptin
repletion on low-leptin states in animal models and humans.
These leptin-deficient states include not only genetic leptin defi-
ciency (very rare in humans) and caloric restriction (including
anorexia), but also other conditions associated with diminished
fat stores and their consequently low or falling leptin concentra-
tions (including lipodystrophy syndromes and untreated insulin
deficiency) (Ahima et al., 1996; Farooqi et al., 1999; GermanCell Metabolism 15, February 8, 2012 ª2012 Elsevier Inc. 151
Figure 2. Potential Sites/Mechanisms Interfering with the
Regulation of Energy Balance to Produce Obesity
Leptin is transported across the blood-brain barrier (BBB) to access first-
order, LEPR-B-expressing neurons, which connect with downstream neurons
to eventually modulate food intake and energy expenditure. Other circuits,
including those not modulated by leptin, also contribute to the control of
feeding and energy expenditure. Interference (red) with any of these
processes, including BBB transport of leptin; cellular processes in LEPR-B
neurons (such as LEPR-B signaling); or alterations in the neural function,
‘‘wiring,’’ or plasticity in any of the leptin-regulated or leptin-independent
circuits that contribute to energy balance are expected to promote obesity
(and increase circulating leptin concentrations).
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2010; Welt et al., 2004; Zhang et al., 1994). Administration of
exogenous leptin mitigates the increased appetite, decreased
energy expenditure, and neuroendocrine dysfunction associ-
ated with each of these states of leptin insufficiency. Leptin
also attenuates the hyperglycemia caused by uncontrolled
insulin-deficient diabetes and lipodystrophy syndromes (Kelesi-
dis et al., 2010; Wang et al., 2010).
The ability of exogenous leptin to reduce food intake/body
weight (and to modulate metabolism and endocrine function) in
the face of replete adipose stores, especially in obese individ-
uals, has proven to be more limited, however (Heymsfield
et al., 1999; Mantzoros and Flier, 2000). Indeed, commensurate
with their large adipose mass, obese individuals exhibit elevated
circulating leptin concentrations relative to lean subjects (Consi-
dine et al., 1996), but these elevated leptin concentrations fail
to return body adiposity to the normal range. In rare instances,
genetic mutations may abrogate LEPR function (here, circulating
leptin is increased to concentrations above those observed in
‘‘normal’’ obese humans of similar fat mass) (Clement et al.,
1998). These instances are similar to classical hormone resis-
tance/insensitivity syndromes (growth hormone insensitivity,
type A insulin resistance, etc.), in which genetic alterations of
the hormone receptor prevent hormone action (Moller and Flier,
1991; Savage et al., 2006).
In the vast majority of human obesity, however, Lepr is unper-
turbed, and obesity and any diminished responsiveness to
leptin must result from other mechanisms. The poor efficacy of
elevated endogenous leptin concentrations to promote leanness
in obese subjects has given rise to the notion of functional ‘‘leptin
resistance,’’ which is often compared to the concept of insulin
resistance in type 2 diabetes—where diminished cellular and152 Cell Metabolism 15, February 8, 2012 ª2012 Elsevier Inc.metabolic insulin responsiveness coexist with the hypersecre-
tion of insulin (Myers et al., 2010; Spiegelman and Flier, 2001).
Implicit in the concept of leptin resistance is the idea that
processes that promote and/or result from obesity impair leptin
action, thereby facilitating the occurrence of obesity and attenu-
ating the potential efficacy of therapy with exogenous leptin.
Understanding mechanisms that may underlie ‘‘leptin resis-
tance’’ is thus crucial both for determining the causes of obesity
and identifying potential mechanisms that can be targeted for
therapy.
While the goal of this NIH conference was to generate a
universal, quantifiable definition of leptin resistance, the common
application of ‘‘leptin resistance’’ to label both the presence of
hyperleptinemia in obesity and the failure of exogenous leptin
administration to provide therapeutic benefit suggests the diffi-
culty of identifying such a universal definition. Regarding the
use of ‘‘leptin resistance’’ to label hyperleptinemia in obesity,
due to their increased adipose tissue mass, virtually all obese
humans and animal models (except some animal strains and
extraordinarily rare patients with genetic leptin deficiency)
display elevated circulating leptin concentrations relative to
lean controls (Considine et al., 1996; Frederich et al., 1995a,
1995b). Additionally, processes other than those attendant to
leptin action and/or LEPR-B signaling per se likely contribute to
the determination of adiposity and etiology of obesity in each
person—including the function and/or anatomic variation of
numerous neural circuits. While some of these circuits may be
directly modulated and/or developmentally programmed by lep-
tin, many are not (Berthoud, 2007; Bouret et al., 2004; Hill et al.,
2008; Horvath and Bruning, 2006; Myers et al., 2010; Pinto
et al., 2004; Ring and Zeltser, 2010) (Figure 2). Furthermore, the
finding that evenveryobese individuals exhibit changes in hunger
and energy expenditure upon moderate weight loss, and that
these changes are blunted by the administration of leptin,
suggests that the elevated levels of leptin in obese individuals
may be functionally relevant (Rosenbaum et al., 2002). Thus,
defining leptin resistance as the coexistence of hyperleptinemia
in obesity merely serves to note the elevated concentration of
a single hormone whose production is expected to be increased
in this condition. Furthermore, leptin retains physiologic rele-
vance even when elevated in obesity, and alterations in leptin
action may or may not be primary to the genesis of obesity.
Thus, referring to the coexistence of hyperleptinemia in obesity
as ‘‘leptin resistance’’ imbues the term with little meaning.
When focusing on the potential therapeutic utility of leptin, the
limited ability of exogenous leptin to promote desired outcomes
represents the central issue, and it is this aspect of the leptin
resistance concept that we will focus on in this review. This
encompases a multitude of situations, however, from assays of
leptin action as diverse as the induction of STAT3 phosphoryla-
tion in the brain (in animal models) and other tissues, to the
attenuation of feeding and the restraint of body weight and
adiposity (in either animals or humans). These may be assayed
following acute or long-term treatment with leptin doses ranging
from the approximately physiologic to the heroically pharmaco-
logic. Practically speaking, therefore, ‘‘leptin resistance’’ is a
term so broadly applied and context dependent that there can




Studies in animal models have suggested a number of basic
mechanisms that may underlie attenuated responsiveness to
leptin.Many of these are processes engaged during or promoted
by overnutrition and obesity, including changes in circulating
leptin-binding proteins, reduced transport of leptin across the
blood-brain barrier, and/or the provocation of processes that
diminish cellular LEPR-B signaling (inflammation, ER stress,
feedback inhibition, etc.) (Bjorbaek et al., 1998, 1999; Bjornholm
et al., 2007; Levin et al., 2004; Lou et al., 2010; Ozcan et al., 2009;
Zabolotny et al., 2002; Zhang and Scarpace, 2009; Zhang et al.,
2008). Alterations in the development of leptin-regulated
neurons and other components of the circuitry that mediates
leptin action could also blunt leptin action throughout life (Bouret
et al., 2004). While differing in their specifics, these potential
explanations for the decreased efficacy of leptin all postulate
that nutritional alterations, obesity (including increased ambient
leptin concentrations themselves [Knight et al., 2010; Qiu et al.,
2001]), or other developmental events impair leptin action.
Indeed, interference with many of the cellular mechanisms that
attenuate LEPR-B signaling improves leptin action in cells and
animal models, revealing that thesemechanisms decrease leptin
action in vivo, as well as suggesting the potential utility of these
processes as points of therapeutic intervention (Bjorbak et al.,
2000; Howard et al., 2004; Ozcan et al., 2009; Zabolotny et al.,
2002). Thus, while it is not possible to precisely define leptin
resistance in a universal, precise, and quantifiable manner, it is
clearly useful to identify and understand mechanisms that may
attenuate leptin action in vivo.
The ‘‘normal’’ response to exogenous leptin, against which
leptin resistance is often defined (especially in rodents), most
often results from the attainment of circulating leptin concentra-
tions thousands of times higher than physiological (Faouzi et al.,
2007), and the anorectic response to these doses is modest
and subject to relatively rapid tachyphylaxis. During evolution,
undernutrition presumably represented a greater threat to
survival than did overnutrition, with the result that the defense
against starvation (low and/or falling leptin) produces stronger
responses than does the defense against nutritional surfeit
(high leptin). A similar line of reasoning posits that the efficacy
of leptin may be near maximal at the concentrations found
in most obese people at baseline, and that the addition of exog-
enous leptin may, therefore, raise circulating leptin concentra-
tions without substantially increasing leptin action. While
a related hypothesis suggests that obesity was also selected
against by factors including the likelihood of predation (Krol
and Speakman, 2007), the ability of palatable calorically dense
diets to promote obesity in most animals and the failure of
elevated leptin levels to reduce body weight in obese animals
suggests that leptin may not play a major role at this end of the
spectrum. The possibility that leptin action may be near its
physiological maximum in states of obesity and the notion that
obesity attenuates leptin action are not mutually exclusive—
both mechanisms may contribute.
Clinical Issues
In human subjects, it is generally not possible to examine the
molecular mechanisms associated with or underlying ‘‘leptin
resistance.’’ Rather, the state must be operationally defined as
decreased responsiveness to leptin by certain criteria. As noted,however, there is no standard for the definition of human ‘‘leptin
resistance.’’ Is leptin resistance defined by the response to
a high or low dose of leptin, given once for a short time or chron-
ically over weeks to months, in patients at baseline or following
some amount of weight reduction? What is the attenuated
response by which we define leptin resistance: decreased food
intake, weight loss, alterations in blood glucose or lipids, hepatic
triglycerides, immune function, etc.?
Since the efficacy of leptin for the control of many metabolic
parameters (e.g., weight, glucose, lipids, hepatic steatosis,
etc.) is likely to be of interest, leptin responsiveness must be
defined in terms of the response of specific parameters, individ-
ually, to leptin treatment.
Clinical Leptin Responsiveness
While clinical ‘‘leptin resistance’’ may be captured in a general
way as poor responsiveness to exogenous leptin, for the reasons
outlined above, it is not possible to define clinical leptin resis-
tance in a precise manner that can be assessed with a single,
universal assay. A pragmatic approach to leptin resistance and
therapeutic leptin action thus focuses not on defining clinical
leptin resistance in a universal manner, but rather on assessing
which individuals are likely to respond to and/or can be sensi-
tized to leptin. While this may seem, on the surface, to be
a semantic argument, it acknowledges that there can be no
universal definition of leptin resistance, and focuses instead on
the more tangible goal of determining whom we can effectively
treat and the parameters of effective treatment.
How to assess leptin sensitivity effectively in the clinical setting
is not currently clear. The available information suggests that, in
general, leptin sensitivity is greatest in those with low adiposity
and low endogenous circulating leptin (Bluher and Mantzoros,
2009). Body adiposity and leptin concentration are unlikely to
represent the only predictors for leptin sensitivity, however, as
each individual is likely to exhibit an idiosyncratic response to
overnutrition or obesity (i.e., in terms of genetic differences or
ER stress or other responses that might limit leptin action).
Indeed, the sexual dimorphism in circulating leptin concentra-
tions suggests underlying differences in leptin production
and/or action by sex (Considine et al., 1996). Similarly, circu-
lating free leptin concentrations are determined not only by
leptin production but by its clearance and by levels of circulating
soluble LEPR (Zhang and Scarpace, 2009). Furthermore, adipo-
nectin and other circulating factors may predict aspects of the
therapeutic efficacy of leptin (Iannucci et al., 2007). Thus, it will
be crucial to assess and report measures of leptin responsive-
ness in large samples of individuals in the context of a variety
of parameters that may affect leptin sensitivity (e.g., age, sex,
BMI, adiposity, fat distribution, circulating levels of leptin, and
other factors, etc.). Also, leptin ismanufactured inmultiple forms,
each with different pharmacodynamics parameters and poten-
tially distinct determinants of efficacy.
In addition to the modulation of body weight and adiposity,
the examination of other potentially useful outcomes of leptin
therapy (e.g., glucose homeostasis, lipid metabolism, hepatic
lipid content, etc.) will be important. Furthermore, as the relation-
ship between potential measures of acute leptin action (e.g.,
24 hr food intake, energy expenditure, leptin-stimulated STAT3
phosphorylation in peripheral blood monocytes, or brain
imaging) and the potential therapeutic chronic effects of leptinCell Metabolism 15, February 8, 2012 ª2012 Elsevier Inc. 153
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term responsiveness of individuals to determine the potential
predictive value of acute studies.
Can Leptin Responsiveness Be Increased?
Some investigators have suggested that pharmacologic interrup-
tion of the cellular mechanisms apparently attenuating LEPR-B
signaling could increase leptin sensitivity (Ozcan et al., 2009).
Indeed, early attempts have met with preliminary success in
animal models. Furthermore, the finding that some compounds
(e.g., the amylin derivative, pramlintide) augment leptin action in
some individuals suggests that it may be possible to increase
the sensitivity of some individuals to therapeutic leptin adminis-
tration (Turek et al., 2010). Whether such a result is a conse-
quence of the initial weight loss induced by a nonleptin drug or
by direct impact of such a drug on leptin receptor signaling, or
mediated by other phenomena remains unclear. Certainly,
however, combinatorial approaches appear to hold some
promise for clinical leptin therapy. As above, for responsiveness
to leptin alone, it will be important to determine traits and/or acute
assays and endpoints that predict the responsiveness of patients
to many types of potential leptin-sensitizing therapies.
Conclusions
While no universal, quantifiable, and clinically useful definition of
the term ‘‘leptin resistance’’ is feasible, defining populations of
patients and/or disease processes that are potentially respon-
sive to leptin therapy will be important. Leptin treatment has
proven therapeutically useful for several clinical indications,
including lipodystrophy syndromes, and is likely to be useful
for numerous others. Identifying predictors of leptin responsive-
ness for numerous clinical indications represents an important
research priority.
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